Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mujahid A Rizvi

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Annals of Internal Medicine|January 22, 2004
Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic reviewSara K Vesely, Jedidiah J Perdue, Mujahid A Rizvi, et al.
Blood|October 8, 2005
T-cell non-Hodgkin lymphomaMujahid A Rizvi, Andrew M Evens, Martin S Tallman, et al.
Molecular Cancer Therapeutics|August 8, 2006
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell linesMujahid A Rizvi, Kulsoom Ghias, Katharine M Davies, et al.
The Journal of Investigative Dermatology|April 29, 2006
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathwayChristiane Querfeld, Mujahid A Rizvi, Timothy M Kuzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2024
Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research StatementRamya Thota, Patricia A Hurley, Therica M Miller, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Annals of Internal Medicine|January 22, 2004
Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic reviewSara K Vesely, Jedidiah J Perdue, Mujahid A Rizvi, et al.
Blood|October 8, 2005
T-cell non-Hodgkin lymphomaMujahid A Rizvi, Andrew M Evens, Martin S Tallman, et al.
Molecular Cancer Therapeutics|August 8, 2006
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell linesMujahid A Rizvi, Kulsoom Ghias, Katharine M Davies, et al.
The Journal of Investigative Dermatology|April 29, 2006
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathwayChristiane Querfeld, Mujahid A Rizvi, Timothy M Kuzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2024
Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research StatementRamya Thota, Patricia A Hurley, Therica M Miller, et al.
Pageof 1